Literature DB >> 20075158

Amino acid residues Arg(659), Arg(660), and Tyr(661) in the spacer domain of ADAMTS13 are critical for cleavage of von Willebrand factor.

Sheng-Yu Jin1, Christopher G Skipwith, X Long Zheng.   

Abstract

Previous studies have shown that ADAMTS13 spacer domain is required for cleavage of von Willebrand factor (VWF). However, the exact amino acid residues within this domain critical for substrate recognition are not known. Epitope mapping of anti-ADAMTS13 immunoglobulin G from patients with thrombotic thrombocytopenic purpura and sequence alignment of the ADAMTS13 spacer domains of human, mouse, and zebrafish with these of human and murine ADAMTS1, a closely related member of ADAMTS family, have provided hints to investigate the role of the amino acid residues between Arg(659) and Glu(664) of the ADAMTS13 spacer domain in substrate recognition. A deletion of all these 6 amino acid residues (ie, Arg(659)-Glu(664)) from the ADAMTS13 spacer domain resulted in dramatically reduced proteolytic activity toward VWF73 peptides, guanidine-HCl denatured VWF, and native VWF under fluid shear stress, as well as ultralarge VWF on endothelial cells. Site-directed mutagenesis, kinetic analyses, and peptide inhibition assays have further identified a role for amino acid residues Arg(659), Arg(660), and Tyr(661) in proteolytic cleavage of various substrates under static and fluid shear stress conditions. These findings may provide novel insight into the structural-function relationship of ADAMTS13 and help us to understand pathogenesis of thrombotic thrombocytopenic purpura and other arterial thromboses associated with compromised VWF proteolysis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20075158      PMCID: PMC2844016          DOI: 10.1182/blood-2009-07-235101

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  43 in total

1.  ADAMTS-1 cleaves a cartilage proteoglycan, aggrecan.

Authors:  K Kuno; Y Okada; H Kawashima; H Nakamura; M Miyasaka; H Ohno; K Matsushima
Journal:  FEBS Lett       Date:  2000-08-04       Impact factor: 4.124

2.  Crystal structures of the noncatalytic domains of ADAMTS13 reveal multiple discontinuous exosites for von Willebrand factor.

Authors:  Masashi Akiyama; Soichi Takeda; Koichi Kokame; Junichi Takagi; Toshiyuki Miyata
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-30       Impact factor: 11.205

3.  Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura.

Authors:  X Zheng; D Chung; T K Takayama; E M Majerus; J E Sadler; K Fujikawa
Journal:  J Biol Chem       Date:  2001-09-13       Impact factor: 5.157

4.  A novel human metalloprotease synthesized in the liver and secreted into the blood: possibly, the von Willebrand factor-cleaving protease?

Authors:  K Soejima; N Mimura; M Hirashima; H Maeda; T Hamamoto; T Nakagaki; C Nozaki
Journal:  J Biochem       Date:  2001-10       Impact factor: 3.387

5.  Partial amino acid sequence of purified von Willebrand factor-cleaving protease.

Authors:  H E Gerritsen; R Robles; B Lämmle; M Furlan
Journal:  Blood       Date:  2001-09-15       Impact factor: 22.113

6.  Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family.

Authors:  K Fujikawa; H Suzuki; B McMullen; D Chung
Journal:  Blood       Date:  2001-09-15       Impact factor: 22.113

7.  Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura.

Authors:  G G Levy; W C Nichols; E C Lian; T Foroud; J N McClintick; B M McGee; A Y Yang; D R Siemieniak; K R Stark; R Gruppo; R Sarode; S B Shurin; V Chandrasekaran; S P Stabler; H Sabio; E E Bouhassira; J D Upshaw; D Ginsburg; H M Tsai
Journal:  Nature       Date:  2001-10-04       Impact factor: 49.962

8.  Multi-step binding of ADAMTS-13 to von Willebrand factor.

Authors:  H B Feys; P J Anderson; K Vanhoorelbeke; E M Majerus; J E Sadler
Journal:  J Thromb Haemost       Date:  2009-09-18       Impact factor: 5.824

9.  A novel binding site for ADAMTS13 constitutively exposed on the surface of globular VWF.

Authors:  Sara Zanardelli; Alain C K Chion; Evelyn Groot; Peter J Lenting; Thomas A J McKinnon; Mike A Laffan; Michelle Tseng; David A Lane
Journal:  Blood       Date:  2009-07-08       Impact factor: 22.113

10.  Leukocyte proteases cleave von Willebrand factor at or near the ADAMTS13 cleavage site.

Authors:  Thomas J Raife; Wenjing Cao; Bonnie S Atkinson; Bruce Bedell; Robert R Montgomery; Steven R Lentz; George F Johnson; X Long Zheng
Journal:  Blood       Date:  2009-06-18       Impact factor: 22.113

View more
  31 in total

1.  Pathogenesis and treatment of acquired idiopathic thrombotic thrombocytopenic purpura.

Authors:  Flora Peyvandi; Roberta Palla; Luca A Lotta
Journal:  Haematologica       Date:  2010-09       Impact factor: 9.941

2.  Multiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients with acquired idiopathic thrombotic thrombocytopenic purpura.

Authors:  X Long Zheng; Haifeng M Wu; Dezhi Shang; Erica Falls; Christopher G Skipwith; Spero R Cataland; Charles L Bennett; Hau C Kwaan
Journal:  Haematologica       Date:  2010-04-07       Impact factor: 9.941

3.  Gain-of-function ADAMTS13 variants that are resistant to autoantibodies against ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura.

Authors:  Cui Jian; Juan Xiao; Lingjie Gong; Christopher G Skipwith; Sheng-Yu Jin; Hau C Kwaan; X Long Zheng
Journal:  Blood       Date:  2012-01-30       Impact factor: 22.113

4.  ADAMTS13 and von Willebrand factor interactions.

Authors:  Catherine B Zander; Wenjing Cao; X Long Zheng
Journal:  Curr Opin Hematol       Date:  2015-09       Impact factor: 3.284

Review 5.  Structure-function and regulation of ADAMTS-13 protease.

Authors:  X L Zheng
Journal:  J Thromb Haemost       Date:  2013-06       Impact factor: 5.824

Review 6.  ADAMTS13 and von Willebrand factor in thrombotic thrombocytopenic purpura.

Authors:  X Long Zheng
Journal:  Annu Rev Med       Date:  2015       Impact factor: 13.739

7.  ADAMTS13 autoantibodies cloned from patients with acquired thrombotic thrombocytopenic purpura: 1. Structural and functional characterization in vitro.

Authors:  Eric M Ostertag; Stephen Kacir; Michelle Thiboutot; Gayathri Gulendran; X Long Zheng; Douglas B Cines; Don L Siegel
Journal:  Transfusion       Date:  2016-04-04       Impact factor: 3.157

8.  Unconjugated bilirubin inhibits proteolytic cleavage of von Willebrand factor by ADAMTS13 protease.

Authors:  R-N Lu; S Yang; H M Wu; X L Zheng
Journal:  J Thromb Haemost       Date:  2015-04-23       Impact factor: 5.824

9.  Carboxyl terminus of ADAMTS13 directly inhibits platelet aggregation and ultra large von Willebrand factor string formation under flow in a free-thiol-dependent manner.

Authors:  Jialing Bao; Juan Xiao; Yingying Mao; X Long Zheng
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-12-19       Impact factor: 8.311

Review 10.  Antigen and substrate withdrawal in the management of autoimmune thrombotic disorders.

Authors:  Douglas B Cines; Keith R McCrae; X Long Zheng; Bruce S Sachais; Eline T Luning Prak; Don L Siegel
Journal:  Blood       Date:  2012-09-10       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.